이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Immunome 관리

관리 기준 확인 1/4

Immunome's CEO는 Clay Siegall, Oct2023 에 임명되었습니다 의 임기는 1년 미만입니다. 총 연간 보상은 $ 15.65M, 1% 로 구성됩니다. 1% 급여 및 99% 보너스(회사 주식 및 옵션 포함). 는 $ 5.57M 가치에 해당하는 회사 주식의 0.7% 직접 소유합니다. 5.57M. 경영진과 이사회의 평균 재임 기간은 각각 0.7 년과 3 년입니다.

주요 정보

Clay Siegall

최고 경영자

US$15.6m

총 보상

CEO 급여 비율	1.0%
CEO 임기	less than a year
CEO 소유권	0.7%
경영진 평균 재임 기간	less than a year
이사회 평균 재임 기간	3.1yrs

최근 관리 업데이트

Recent updates

CEO 보상 분석

Clay Siegall 의 보수는 Immunome 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Mar 31 2024	n/a	n/a	-US$232m
Dec 31 2023	US$16m	US$163k	-US$107m

보상 대 시장: Clay 의 총 보상 ($USD 15.65M )은 US 시장( $USD 3.43M ).

보상과 수익: Clay 의 보상을 회사 성과와 비교하기에는 데이터가 부족합니다.

CEO

Clay Siegall (63 yo)

less than a year

테뉴어

US$15,648,944

보상

Dr. Clay B. Siegall, Ph D., serves as Independent Chairman since December 13, 2023 at Tourmaline Bio, Inc. He served as Chief Executive Officer & President of Morph Immune, Inc. from March 2023 until Octob...

리더십 팀

이름	위치	테뉴어	보상	소유권
Clay Siegall	President	less than a year	US$15.65m	0.70% $ 5.1m
Jack Higgins	Chief Scientific Officer	less than a year	US$2.17m	0% $ 0
Robert Lechleider	Chief Medical Officer	less than a year	US$3.22m	데이터 없음
Max Rosett	Executive VP of Operations	less than a year	데이터 없음	0.033% $ 240.3k
Philip Tsai	Chief Technology Officer	no data	데이터 없음	데이터 없음
Sandra Stoneman	Chief Legal Officer	3.8yrs	US$1.64m	0.0093% $ 67.2k
Bruce Turner	Chief Strategy Officer	less than a year	데이터 없음	0.071% $ 511.9k
Kinney Horn	Chief Business Officer	less than a year	데이터 없음	데이터 없음

0.8yrs

평균 재임 기간

51yo

평균 연령

경험이 풍부한 관리: IMNM 의 관리팀은 경험 (평균 재직 기간 0.7 년)으로 간주되지 않으므로 새로운 팀을 추천합니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Clay Siegall	President	less than a year	US$15.65m	0.70% $ 5.1m
Louis Weiner	Member of Scientific Advisory Board	no data	데이터 없음	데이터 없음
Philip Wagenheim	Director	6.6yrs	US$59.23k	0.65% $ 4.8m
George Prendergast	Member of Scientific Advisory Board	no data	데이터 없음	데이터 없음
Isaac Barchas	Lead Independent Director	less than a year	US$296.59k	0.15% $ 1.1m
James Boylan	Independent Director	less than a year	US$294.75k	0% $ 0
Andrew Badley	Member of COVID-19 Advisory Board	3.1yrs	데이터 없음	데이터 없음
Carol Schafer	Independent Director	less than a year	데이터 없음	0% $ 0
William Strohl	Member of Scientific Advisory Board	no data	데이터 없음	데이터 없음
Jeffrey Henderson	Member of COVID-19 Advisory Board	3.8yrs	데이터 없음	데이터 없음
Shmuel Shoham	Member of COVID-19 Advisory Board	3.8yrs	데이터 없음	데이터 없음
Susan Weiss	Member of COVID-19 Advisory Board	3.8yrs	데이터 없음	데이터 없음

3.1yrs

평균 재임 기간

60yo

평균 연령

경험이 풍부한 이사회: IMNM 의 이사회는 경험(평균 재직 기간 3 년)으로 간주됩니다.

Immunome 관리

관리 기준 확인 1/4

주요 정보

최근 관리 업데이트

Immunome, Inc. Appoints Phil Tsai as Chief Technical Officer

President recently bought US$1.4m worth of stock

Immunome, Inc. Announces Promotion of Max Rosett to Chief Financial Officer

Immunome, Inc. Appoints Kinney Horn as Chief Business Officer

Immunome, Inc., Annual General Meeting, Jun 12, 2024

Immunome, Inc. Appoints Sandra M. Swain to Board of Directors

Recent updates

Immunome, Inc. Appoints Phil Tsai as Chief Technical Officer

President recently bought US$1.4m worth of stock

Consensus EPS estimates fall by 97%, revenue upgraded

Immunome, Inc. (NasdaqCM:IMNM) completed the acquisition of Substantially all Assets of Atreca, Inc. (NasdaqGS:BCEL).

Immunome, Inc. Announces Promotion of Max Rosett to Chief Financial Officer

Immunome, Inc. has filed a Follow-on Equity Offering in the amount of $200 million.

Immunome, Inc. Appoints Kinney Horn as Chief Business Officer

Immunome, Inc., Annual General Meeting, Jun 12, 2024

Immunome, Inc. Appoints Sandra M. Swain to Board of Directors

Consensus EPS estimates fall by 17%

Immunome, Inc. (NasdaqCM:IMNM) completed the acquisition of Assets from Ayala Pharmaceuticals, Inc. (OTCPK:ADXS).

Immunome, Inc. has completed a Follow-on Equity Offering in the amount of $200 million.

Immunome, Inc. has completed a Follow-on Equity Offering in the amount of $200 million.

New minor risk - Share price stability

Immunome, Inc. Announces Promotion of Max Rosett to Executive Vice President, Operations

Consensus EPS estimates upgraded to US$0.97 loss

Immunome: Why It Has Doubled Over The Last Month

Immunome Appoints Phil Roberts as Chief Technical Officer

Immunome, Inc. Announces Board Changes

Immunome, Inc. Announces Executive Changes, Effective January 2, 2024

Immunome, Inc. announced that it has received $124.722508 million in funding from Enavate Sciences, EcoR1 Capital, LLC, Redmile Group, LLC, Janus Henderson Group plc, Avidity Partners Management, L.P., Woodline Partners LP and other investors

Immunome, Inc. Appoints Jean-Jacques Bienaimé to Board of Directors

Immunome Appoints Bob Lechleider as Chief Medical Officer

Less than half of directors are independent

New major risk - Shareholder dilution

Immunome, Inc. (NasdaqCM:IMNM) entered into an agreement to acquire MorphImmune, Inc. from Research Bridge Partners, Investment Arm and others for $51.7 million.

Immunome, Inc. announced that it expects to receive $124.722508 million in funding

No longer forecast to breakeven

Will Immunome (NASDAQ:IMNM) Spend Its Cash Wisely?

Immunome, Inc. Announces Formation of Antibody-Drug Conjugate and T Cell Redirection Advisory Board

Is Immunome (NASDAQ:IMNM) In A Good Position To Deliver On Growth Plans?

Price target decreased to US$8.50

High number of new directors

Immunome Presents Preclinical Data on Novel Anti-EPN1 Antibody IMM20059 at the Society for Immunotherapy of Cancer’s (SITC) 37th Annual Meeting

Forecast to breakeven in 2024

Immunome Announces Publication in Clinical & Translational Immunology Highlighting B Cell Repertoires in Patients with Breast Cancer

Immunome GAAP EPS of -$0.74

Here's Why We're Watching Immunome's (NASDAQ:IMNM) Cash Burn Situation

Immunome, Inc.’S Covid-19 Cocktail Retains Neutralizing Activity Against the Most Prevalent Omicron Subvariants in the Us, Ba.4/5 and Ba.2.12.1

Immunome gains 34% after preclinical data on COVID-19 antibody

Immunome, Inc. Announces Initiation of Phase 1b Study of IMM-BCP-01 for the Treatment of COVID-19

Immunome, Inc. Provides Research & Development Update on Lead Oncology Candidate Targeting IL-38

Immunome, Inc. Announces Data Demonstrating COVID-19 Antibody Cocktail Potently Clears Omicron BA.1 Variant in Hamster Model and Retains Activity Against BA.2 Subvariant

Immunome, Inc., Annual General Meeting, Jun 15, 2022

High number of new and inexperienced directors

Price target increased to US$33.00

We Think Immunome (NASDAQ:IMNM) Can Afford To Drive Business Growth

Immunome, Inc. Antibody Cocktail Effective Against SARS-CoV-2 Omicron Variant in Vitro Live Virus Testing

Immunome Provides Update on Investigational New Drug Application for IMM-BCP-01 for the Treatment of COVID-19

Immunome, Inc. Expects IMM-BCP-01 Antibody Cocktail to Neutralize the SARS-CoV-2 Omicron Variant

Immunome Announces Submission of Investigational New Drug (IND) Application for IMM-BCP-01 for the Treatment of COVID-19

Companies Like Immunome (NASDAQ:IMNM) Are In A Position To Invest In Growth

Immunome, Inc.(NasdaqCM:IMNM) dropped from Russell 3000E Growth Index

Director recently bought US$248k worth of stock

Immunome SARS-CoV-2 Antibody Cocktail Neutralizes UK, South Africa, Brazil and California Variants in Preclinical Testing; Progressing Towards IND Filing

Immunome launches $27M private placement

Do Institutions Own Immunome, Inc. (NASDAQ:IMNM) Shares?

Immunome, Inc. Discovers Antibodies Capable of Neutralizing Multiple SARS-CoV-2 Variants, Including the South African Variant, in Pseudovirus Testing

New 90-day high: US$39.01

Abzena Selects Immunome, Inc.’s Partner Research Organization for IMM-BCP-01

New 90-day high: US$20.24

Read This Before Selling Immunome, Inc. (NASDAQ:IMNM) Shares

New 90-day high: US$13.73

Immunome, Inc. Appoints Diane Marcou as Interim Chief Financial Officer

Immunome EPS misses by $7.22

Key Executive recently bought US$1m worth of stock

Immunome, Inc. has completed an IPO in the amount of $39 million.

CEO 보상 분석

CEO